GLP-1 receptor agonists and chronic obstructive pulmonary disease (COPD)
A longitudinal cohort study was undertaken to compare the risk of cardiopulmonary outcomes in patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD) using glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) (1):
- registry study in Taiwan (8,060 matched GLP-1 receptor agonists (RA) users and non-users with COPD and type 2 diabetes) found those on GLP-1 RA had a lower risk of mortality (adjusted hazard ratio 0.46, 95%CI 0.38-0.56), cardiovascular events (0.73, 0.65-0.82), and bacterial pneumonia (0.76, 0.65-0.80
Study authors concluded:
- study showed that GLP-1 RAs had a lower risk of cardiopulmonary outcomes and all-cause mortality than non-GLP1 RAs in patients with T2D and COPD
- GLP-1 RAs may help manage diabetes in people with COPD
Reference:
- Yen FS, Hsu CC, Wei JC, Tsai FJ, Huang Y, Yu TS, Hwu CM. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024 Oct 1:thorax-2023-221040. doi: 10.1136/thorax-2023-221040.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.